Ann Arbor, Mich. – Early treatment of pediatric Crohn’s disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn’s disease. Michigan Medicine researchers confirmed this finding using prospective data. The resulting paper, “Early tumour necrosis factor antagonist treatment prevents perianal...
treatment News
Ottawa, Canada – Glioblastoma is the most common – and the most malignant – primary brain tumour in adults. It’s aggressive and incurable. Even with treatment including surgical removal and chemotherapy, the median survival for patients is just 18 months. Now, innovative new research led by Dr. Arezu Jahani-Asl, Canada Research Chair in Neurobiology of...
PITTSBURGH, PA – A self-destructing vaccine administered intravenously provides additional safety and protection against tuberculosis (TB) in macaque monkeys, suggests new University of Pittsburgh research published today in Nature Microbiology. The in-built safety mechanisms circumvent the possibility of an accidental self-infection with weakened mycobacteria, offering a safe and effective way...
Houston, Texas – Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II trial results published today in Nature Cancer by researchers at The University of Texas MD Anderson Cancer Center. After treatment...
SAN FRANCISCO, Calif. — Unlearn®, a leader in AI-powered solutions for clinical trials, today announced a collaboration with Trace Neuroscience, a biotechnology company focused on developing genomic therapies for neurodegenerative diseases. The partnership will support Trace Neuroscience as the company plans its upcoming Phase 1/2 clinical trial in amyotrophic lateral...
Beijing, China – Brain cancer is one of the most aggressive and life-threatening diseases, with glioblastoma (GBM) being the most common and deadliest type. Patients often experience debilitating symptoms, including headaches, seizures, memory loss, and personality changes, all of which drastically reduce quality of life. Despite progress in surgery, radiotherapy,...
BOSTON, Mass. — Unravel Biosciences, Inc., (“Unravel”), a clinical stage therapeutics company established to advance drugs for complex diseases through its Predictable Medicine™ platform, today announced the first study participants have been dosed in Unravel’s RVL-001 clinical trials for Rett syndrome (“RTT”) and Pitt Hopkins syndrome (“PTHS”). RVL-001, a proprietary...
PITTSBURGH, Pennsylvania, and JERUSALEM, Israel — The University of Pittsburgh Cancer Institute (UPCI) and the Gamida Cell – Teva Joint Venture announced today that the Institute has joined an elite group of cancer centers in Europe, the United States and Israel that are now enrolling patients to participate in the...
AstraZeneca, Swedish Orphan Biovitrum AB (publ) (Sobi) and Sanofi have updated and simplified their contractual arrangements relating to the development and commercialisation of nirsevimab in the US. Given the upcoming launch of nirsevimab in the US and other markets, simplification of the prior arrangements clarifies the roles and responsibilities of...
Treatment-free remission (TFR) is feasible after 2 or more years of frontline nilotinib treatment in patients with chronic myeloid leukemia in chronic phase (CML-CP), reported researchers in a study published in Leukemia. Advances in the treatment of CML have improved outcomes for those with the disease; however, long-term treatment with tyrosine...